Split History
8% "No Withdrawal" Portfolio »    XPH Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
SPDR S&P Pharmaceuticals is an open-end investment management company. The Fund seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. As of June 30 2015, the Fund's total assets and investment portfolio totaled $1,324,794,738 and $1,323,892,831, respectively. According to our XPH split history records, SPDR Series Trust - S&P Pharmaceuticals ETF has had 1 split.
XPH split history picture
SPDR Series Trust - S&P Pharmaceuticals ETF (XPH) has 1 split in our XPH split history database. The split for XPH took place on September 11, 2015. This was a 2 for 1 split, meaning for each share of XPH owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as SPDR Series Trust - S&P Pharmaceuticals ETF splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.

Looking at the XPH split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SPDR Series Trust - S&P Pharmaceuticals ETF shares, starting with a $10,000 purchase of XPH, presented on a split-history-adjusted basis factoring in the complete XPH split history. XPH split adjusted history picture

Growth of $10,000.00
With Dividends Reinvested

Start date: 02/22/2010
End date: 02/19/2020
Start price/share: $19.16
End price/share: $46.48
Starting shares: 521.92
Ending shares: 641.57
Dividends reinvested/share: $9.59
Total return: 198.20%
Average Annual Total Return: 11.55%
Starting investment: $10,000.00
Ending investment: $29,823.99
Years: 10.00
 
Growth of $10,000.00
Without Dividends Reinvested

Start date: 02/22/2010
End date: 02/19/2020
Start price/share: $19.16
End price/share: $46.48
Dividends collected/share: $9.59
Total return: 192.65%
Average Annual Total Return: 11.34%
Starting investment: $10,000.00
Ending investment: $29,267.41
Years: 10.00
Date Ratio
09/11/20152 for 1
XPH is categorized under the Financials sector; below are some other companies in the same sector that also have a history of stock splits:

XRT Split History
XSD Split History
XSW Split History
XTN Split History
Y Split History
YANG Split History
YDKN Split History
ZF Split History
ZION Split History
ZTR Split History

Also explore: XPH shares outstanding history

Brookfield Asset Management Inc. (BAM)
Bellerophon Therapeutics, Inc. (BLPH)
Bellicum Pharmaceuticals, Inc. (BLCM)
SenesTech, Inc. (SNES)
ContraFect Corporation (CFRX)
Gulf Resources, Inc. (GURE)
Sierra Oncology, Inc. (SRRA)
Yield10 Bioscience, Inc. (YTEN)
Phio Pharmaceuticals Corp. (PHIO)
Inpixon (INPX)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

XPH Split History | www.SplitHistory.com | Copyright © 2013 - 2020, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.